What this is
- How it works
- How it works isn't classified yet
- Tested for
- Pneumococcal Disease, Invasive
- Main trialPhase 2
- “Phase 2 trial to evaluate safety and immunogenicity of Inventprise's (IVT) 25-valent pneumococcal conjugate vaccine (IVT PCV-25) in Healthy Infants”In the company’s words, NCT06790290 on ClinicalTrials.gov
- Other names
- Formulation B · Formulation C · Formulation D
Other drugs for Pneumococcal Disease, Invasive
- 13-Valent Pneumococcal Polysaccharide Conjugate VaccineCanSino Biologics Inc. · Phase 3
- 20vPCVSanofi · Phase 3
- Pneumococcal Conjugate VaccineSanofi · Phase 3
- PG4Pfizer · Phase 3
- Pneumococcal conjugate vaccinePfizer · Phase 3
- PrevnarPfizer · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 3 Apr 2025 | Phase 2 Trial to Evaluate Safety and Immunogenicity of Inventprise's (IVT) 25-valent Pneumococcal Conjugate Vaccine (IVT PCV-25) in Healthy Infants | |
| Phase 2Completed | 24 May 2024 | Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine | |
| Phase 1Completed | 31 Jul 2023 | Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026